In conclusion, our study provides compelling evidence for exarafenib’s therapeutic potential in BRAF-mutated NSCLC and establishes the mechanistic foundation for rational combination strategies currently being evaluated clinically. This evidence concerns the gene BRAF and non-small cell lung carcinoma.